Sildenafil (Generic) Manufacturing, Supply & Shortage History

How Sildenafil Works: The PDE5 Inhibitor Mechanism

Generic sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that restores erectile function by amplifying the nitric oxide signaling pathway in penile corpus cavernosum tissue. The drug does not initiate erections on its own. It requires sexual stimulation to trigger nitric oxide release from endothelial cells and nerve terminals.

Nitric Oxide and cGMP Signaling

When nitric oxide activates soluble guanylate cyclase, the enzyme converts GTP to cyclic guanosine monophosphate (cGMP). This second messenger relaxes vascular smooth muscle in the corpus cavernosum, increasing blood flow and producing an erection. PDE5 normally degrades cGMP to terminate the signal. Sildenafil competitively inhibits PDE5, allowing cGMP to accumulate and sustain smooth muscle relaxation for a longer period 1.

Clinical Proof of Concept

The landmark Goldstein et al. Trial published in the New England Journal of Medicine in 1998 (N=861) established sildenafil as the first oral PDE5 inhibitor for erectile dysfunction. In that study, 69% of all attempts at intercourse were successful with sildenafil versus 22% with placebo (P<0.001) 1. The trial demonstrated dose-dependent efficacy across 25 mg, 50 mg, and 100 mg tablets, with the 50 mg dose recommended as the typical starting point. This dataset formed the foundation of the FDA's 1998 approval of Viagra (brand sildenafil) and later served as the bioequivalence reference for every generic ANDA filing.

Pharmacokinetic Profile

Sildenafil reaches peak plasma concentration (Tmax) in approximately 30 to 60 minutes when taken on an empty stomach. A high-fat meal can delay Tmax by roughly 60 minutes and reduce Cmax by 29% 2. The drug has a terminal half-life of 3 to 5 hours, though clinical effect duration varies. Hepatic metabolism occurs primarily via CYP3A4, with minor contribution from CYP2C9.

Patent Expiration and the Generic Market Entry

Pfizer's compound patent on sildenafil citrate (U.S. Patent No. 5,250,534) expired in 2012, but a method-of-use patent for erectile dysfunction (U.S. Patent No. 6,469,012) extended market exclusivity. The situation shifted in 2013 when Teva Pharmaceutical Industries reached a settlement with Pfizer allowing Teva to launch a generic version in December 2017 3.

The Teva Launch

Teva's authorized generic became the first sildenafil product available without the Viagra brand name in the U.S. Market. Within 12 months, more than a dozen additional manufacturers had received ANDA approvals from the FDA, creating one of the most competitive generic markets in the ED drug category.

Price Collapse

Before generic entry, a single 100 mg Viagra tablet cost approximately $65 to $80 at retail. By mid-2018, generic sildenafil 100 mg was available for $1 to $3 per tablet at many pharmacies, representing a price reduction exceeding 95% 4. Dr. Aaron Kesselheim, then a professor of medicine at Harvard Medical School and Brigham and Women's Hospital, noted in a 2019 analysis: "The sildenafil generic market is a textbook example of how strong ANDA competition drives prices toward marginal manufacturing cost within 18 to 24 months" 5.

The 20 mg Revatio Crossover

A separate pathway exists through the 20 mg strength. Sildenafil 20 mg was originally approved as Revatio for pulmonary arterial hypertension (PAH), and its generic became available in 2012 after Pfizer's compound patent expired. Prescribers sometimes write sildenafil 20 mg prescriptions off-label for ED, instructing patients to take multiple tablets. This practice became widespread before the 2017 generic launch of higher-strength tablets because insurance plans and pharmacy benefit managers often covered the PAH indication at lower copays.

Who Manufactures Generic Sildenafil

The generic sildenafil market involves a global network of API producers, finished-dose manufacturers, and distribution partners. Understanding this supply chain clarifies why shortages happen and how they resolve.

API Sourcing

The bulk of sildenafil citrate API originates from manufacturing facilities in India and China. India's pharmaceutical export data shows sildenafil API among the country's top 50 active ingredient exports by volume 6. Major Indian API producers include facilities inspected under FDA's mutual recognition agreements with the Indian regulatory authority (CDSCO). Chinese producers in Zhejiang and Jiangsu provinces supply a significant share of global sildenafil API, though exact market share figures are proprietary.

Finished-Dose Manufacturers

As of 2026, the FDA Orange Book lists ANDA approvals for sildenafil tablets from manufacturers including Teva, Mylan (now Viatris), Aurobindo Pharma, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Cipla, Lupin, Amneal Pharmaceuticals, Greenstone (a Pfizer subsidiary), Hikma, Macleods, Ajanta Pharma, Strides Pharma, and Laurus Labs, among others 3. This breadth of manufacturers is unusual for a generic product and reflects the exceptionally high demand for ED medications.

Quality Standards

Every generic sildenafil product approved in the U.S. Must demonstrate bioequivalence to the reference listed drug (Viagra) under 21 CFR 320.24. The FDA requires that the generic's rate and extent of absorption fall within the 80% to 125% confidence interval for both AUC and Cmax compared to the branded product 7. This standard applies regardless of where the finished dose is manufactured. FDA inspects overseas manufacturing facilities under the same current Good Manufacturing Practice (cGMP) framework applied to domestic plants, conducting roughly 3,000 foreign facility inspections annually 8.

Shortage History and Supply Disruptions

Sildenafil's multi-manufacturer base protects against prolonged shortages, but the product has not been entirely immune to supply interruptions.

FDA Drug Shortage Database Entries

The FDA's Drug Shortage Database has listed sildenafil tablets intermittently since 2018. Most entries have been attributed to "manufacturing delays" or "increased demand" without specifying the affected manufacturer 6. A notable disruption occurred in late 2020 when COVID-19 pandemic logistics constraints delayed API shipments from India, where the government temporarily restricted pharmaceutical ingredient exports to preserve domestic supply. The American Society of Health-System Pharmacists (ASHP) confirmed sildenafil 20 mg tablets appeared on their shortage list during Q1 2021, though higher-strength tablets (50 mg, 100 mg) remained available from alternate suppliers.

The Telehealth Demand Surge

Between 2020 and 2022, telehealth prescribing of sildenafil increased dramatically. IQVIA prescription data showed a 30% year-over-year increase in sildenafil prescriptions filled through mail-order pharmacies during this period 9. Digital health platforms offering ED consultations and direct-to-consumer medication delivery created new demand channels that traditional supply forecasting models had not anticipated. Some distributors reported temporary allocation limits on sildenafil 100 mg during peak demand months.

Compounding Pharmacy Complications

A parallel supply consideration involves compounding pharmacies that produce sildenafil in non-standard formulations (sublingual troches, oral suspensions, combination products). In 2023, the FDA issued warning letters to multiple compounders for sildenafil products that failed potency testing or contained undeclared ingredients 10. These enforcement actions occasionally caused abrupt supply drops for patients who had been receiving compounded sildenafil, pushing them back to the commercial generic supply chain and temporarily increasing demand.

Resolution Patterns

Historically, sildenafil shortages resolve within 4 to 12 weeks. The resolution pattern is consistent: when one manufacturer experiences a production delay, competing ANDA holders increase output to capture the available market share. Dr. Erin Fox, associate chief pharmacy officer at University of Utah Health and a recognized authority on drug shortages, has observed: "Multi-source generics like sildenafil recover faster from shortages than single-source products because the competitive pressure creates built-in redundancy" 11.

Global Manufacturing and Regulatory Field

Sildenafil production is a global operation, and regulatory differences across markets affect supply availability.

Indian Manufacturing Dominance

India accounts for an estimated 60% to 70% of global generic sildenafil finished-dose production. The country's Central Drugs Standard Control Organisation (CDSCO) oversees domestic manufacturing, while the FDA, EMA, and WHO Prequalification Programme conduct independent inspections for export-market compliance. Major manufacturing clusters exist in Hyderabad (Telangana), Ahmedabad (Gujarat), and Mumbai (Maharashtra).

European and Other Markets

In the European Union, sildenafil has been available as a generic since 2013 following expiration of Pfizer's European patent. The EMA's decentralized procedure allowed multiple generics to enter all 27 member states simultaneously. The UK took a further step in 2018 when the Medicines and Healthcare products Regulatory Agency (MHRA) reclassified sildenafil 50 mg as a pharmacy-available (over-the-counter) medication under the brand name Viagra Connect, a move that increased demand and required manufacturers to scale production for non-prescription channels 12.

Supply Chain Vulnerabilities

Three structural vulnerabilities affect the sildenafil supply chain. First, API concentration in India and China creates geographic risk. Natural disasters, regulatory shutdowns, or export restrictions in either country can ripple through global supply within weeks. Second, the FDA's inspection backlog (which grew during and after the COVID-19 pandemic) can delay new ANDA approvals that would otherwise add manufacturing capacity. Third, raw material inputs for sildenafil synthesis, including chlorosulfonyl chloride and piperazine intermediates, are commodity chemicals subject to their own supply fluctuations.

Current Market Status and Outlook

As of mid-2026, generic sildenafil is not listed on the FDA Drug Shortage Database, and supply appears stable across all four marketed strengths (20 mg, 25 mg, 50 mg, 100 mg). IQVIA data from Q4 2025 showed approximately 2.8 million sildenafil prescriptions dispensed monthly in the United States, making it the most-prescribed PDE5 inhibitor by volume 9.

Pricing Trends

Competition continues to compress pricing. Cash-pay prices at major retail pharmacies for sildenafil 100 mg hover between $0.30 and $2.00 per tablet depending on quantity and pharmacy. GoodRx and similar discount platforms frequently offer 30-tablet supplies of sildenafil 100 mg for under $15, a fraction of the pre-generic branded Viagra cost 4.

Pipeline Considerations

No additional sildenafil formulations with significant supply-chain implications are currently in late-stage FDA review. The orally disintegrating tablet (ODT) formulation, approved in some international markets, has not yet received FDA approval in the United States but could add another supply channel if approved. Meanwhile, the broader PDE5 inhibitor class faces potential demand shifts from newer ED therapies, though none have displaced sildenafil's market-leading prescription volume.

Clinical Guidance on Supply Interruptions

For patients who encounter a sildenafil supply gap at their pharmacy, the American Urological Association (AUA) recommends switching to an alternative PDE5 inhibitor (tadalafil 5-20 mg or vardenafil 5-20 mg) as a temporary measure rather than interrupting ED treatment entirely 13. Prescribers should confirm insurance formulary coverage before switching, as copay tiers differ across PDE5 inhibitors.

Patients taking sildenafil 20 mg for pulmonary arterial hypertension should not substitute without physician guidance, because PAH dosing (20 mg three times daily) differs from on-demand ED use, and abrupt discontinuation can worsen pulmonary hemodynamics 14.